<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of bradycardia in the operating room: Rapid overview*&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of bradycardia in the operating room: Rapid overview*<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of bradycardia in the operating room: Rapid overview*<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><tbody> <tr class="divider_bottom"> <td>Intraoperative bradycardia with HR &lt;60 bpm or rapidly decreasing HR with hemodynamic instability (ie, causing hypotension or poor perfusion)<sup>¶</sup></td> </tr> <tr> <td class="subtitle1_single">Identify and treat potential causes of bradycardia</td> </tr> <tr> <td class="indent1"> <ul> <li>Vagal reflexes <ul> <li>Initial treatment: cease surgical or interventional stimulus (eg, oculocardiac reflex during ophthalmic surgery, peritoneal stretching during laparoscopic surgery) </li> <li>Persistent bradycardia: atropine 0.5 mg (may repeat up to a total of 3 mg) in a hemodynamically unstable patient; or glycopyrrolate 0.2 mg (may repeat up to a total of 1 mg) in a hemodynamically stable patient </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Neuraxial anesthesia with a high (ie, T1 to T4) anesthetic level <ul> <li>Initial treatment: ephedrine 5 to 10 mg or epinephrine 10 to 20 mcg </li> <li>Persistent or severe bradycardia: larger doses of epinephrine (ie, 100 mcg) and/or continuous epinephrine infusion, as well as atropine 0.5 mg (may repeat up to a total of 3 mg) </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Medications that increase risk for sinus bradycardia (chronically or acutely administered) <ul> <li>Negative chronotropic agents (eg, beta blockers, calcium channel blockers) <ul> <li>Initial treatment: ephedrine 5 to 10 mg </li> <li>Persistent or severe bradycardia: epinephrine 10 to 20 mg and/or continuous epinephrine infusion, as well as atropine 0.5 mg (may repeat up to a total of 3 mg) </li> </ul> </li> <li>Anticholinesterase agents, opioids, vasoconstrictors <ul> <li>Initial treatment: glycopyrrolate 0.2 mg (may repeat up to a total of 1 mg) </li> <li>Persistent or severe bradycardia: atropine 0.5 mg (may repeat up to a total of 3 mg) </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Auto-PEEP or high peak inspiratory pressures <ul> <li>Initial treatment: hand ventilation with attention to airway pressures </li> <li>Persistent or severe bradycardia: atropine 0.5 mg (may repeat up to a total of 3 mg) </li> </ul> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Less common causes of bradycardia: identify and treat as needed: <ul> <li>"H's": hydrogen ion (ie, acidemia), hypoglycemia, hypokalemia, hyperkalemia, hypermagnesemia, hypothermia, hyperthermia (ie, malignant hyperthermia) </li> <li>"T's": tamponade, tension pneumothorax </li> <li>Myocardial ischemia </li> <li>Local anesthetic systemic toxicity (LAST) </li> <li>Exacerbation of pulmonary hypertension </li> </ul> </li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Persistent bradycardia that does not respond to pharmacologic treatment</td> </tr> <tr> <td class="indent1"> <ul> <li>Temporary pacing <ul> <li>Initial treatment: transcutaneous pacing </li> <li>Persistent bradycardia: prepare for transvenous pacing (ie, insertion of a pacing lead or pacing PA catheter) via central venous access </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Expert cardiology consultation </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Transfer to intensive care unit for postoperative management </li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Severe or persistent bradycardia progressing to asystole, pulseless electrical activity (PEA)</td> </tr> <tr> <td class="indent1"> <ul> <li>Begin CPR and ACLS and call for help (in addition to treatments listed above)<sup>Δ</sup> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Consider other therapies<sup>◊</sup> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">HR: heart rate; bpm: beats per minute; PEEP: positive end-expiratory pressure; PA: pulmonary artery; CPR: cardiopulmonary resuscitation; ACLS: advanced cardiac life support.<br/>* Refer to UpToDate content discussing arrhythmias during anesthesia and perioperative ACLS.<br/>¶ A HR of 40 to 60 bpm without symptoms is common during general anesthesia, and does not require treatment.<br/>Δ Refer to UpToDate content discussing basic life support and ACLS.<br/><span class="lozenge">◊</span> Refer to UpToDate content discussing therapies of uncertain benefit in basic and advanced cardiac life support.</div><div class="graphic_reference">Reference:

<ol>
<li>Moitra VK, Elnav S, Thies K-C, et al. Cardiac arrest in the operating room: Resuscitation and management for the anesthesiologist. Anesth Analg 2018; 126:876.</li>
</ol></div><div id="graphicVersion">Graphic 127098 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
